Facts and prospects of peptide in targeted therapy and immune regulation against triple-negative breast cancer

Frontiers in Immunology

Immunology

Anqi Zeng¹  Linjiang Song²  Yongxiu Huang² 

[1] Institute of Translational Pharmacology and Clinical Application, Sichuan Academy of Chinese Medical Science, Chengdu, Sichuan, China;School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China;

关键词: triple-negative breast cancer;    peptide;    immunity;    target;    combination;   

DOI  :  10.3389/fimmu.2023.1255820

 received in 2023-07-09, accepted in 2023-08-11,  发布年份 2023

来源: Frontiers

【 摘 要 】

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Due to the lack of specific therapeutic targets, treatment options are limited, and the recurrence and metastasis rate is high, the overall survival of patients is poor. However, with the discovery of some new targets and the corresponding immune regulation after targeting these targets, TNBC has a new hope in treatment. The peptide has a simple structure, strong binding affinity, and high stability, and has great potential in targeted therapy and immune regulation against TNBC. This review will discuss how single peptides and peptide combinations target triple-negative breast cancer to exert immunomodulatory effects. Among them, single peptides target specific receptors on TNBC cells, act as decoys to target key ligands in the regulatory pathway, and target TME-related cells. The combinations of peptides work in the form of cancer vaccines, engineered exosomes, microRNAs and other immune-related molecular pathways, immune checkpoint inhibitors, chimeric antigen receptor T cells, and drug-peptide conjugates. This article is mainly dedicated to exploring new treatment methods for TNBC to improve the curative effect and prolong the survival time of patients.

【 授权许可】

Unknown   
Copyright © 2023 Huang, Zeng and Song